FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer
<b>Background:</b> Albumin-bound paclitaxel (nab-PTX) nanoparticles have been proven effective in treating advanced pancreatic cancer. However, the clinical application of nab-PTX nanoparticles is often associated with suboptimal outcomes and severe side effects due to its non-specific d...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/12/1666 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850239443233931264 |
|---|---|
| author | Jian Wang Nianhui Yu Yunpeng Tang Yingsheng Cheng Hui Li |
| author_facet | Jian Wang Nianhui Yu Yunpeng Tang Yingsheng Cheng Hui Li |
| author_sort | Jian Wang |
| collection | DOAJ |
| description | <b>Background:</b> Albumin-bound paclitaxel (nab-PTX) nanoparticles have been proven effective in treating advanced pancreatic cancer. However, the clinical application of nab-PTX nanoparticles is often associated with suboptimal outcomes and severe side effects due to its non-specific distribution and rapid clearance. This study aims to develop a novel nanoplatform that integrates sonodynamic therapy (SDT) and chemotherapy to enhance treatment efficacy and reduce systemic side effects. <b>Methods:</b> Bovine serum albumin (BSA) was conjugated with chlorin e6 and paclitaxel (PTX) to form stable nanoparticles (NPs). These NPs were then incorporated into a biodegradable poly(lactic-<i>co</i>-glycolic acid)–<i>b</i>-polyethylene glycol–<i>b</i>–poly(lactic-<i>co</i>-glycolic acid) hydrogel for targeted drug delivery. The system’s stability and drug release profile were analyzed, followed by in vitro studies to evaluate cellular uptake and cancer cell killing efficacy. In vivo evaluation was performed using pancreatic cancer xenograft models, with intratumoral injection of the drug-loaded hydrogel. <b>Results:</b> The developed hydrogel system demonstrated enhanced stability and sustained release of PTX. In vitro analyses revealed significant cellular uptake and synergistic cancer cell killing effects through combined SDT and chemotherapy. In vivo studies showed prolonged intratumoral retention of the drug and remarkable inhibition of tumor growth. <b>Conclusions:</b> This novel nanoplatform offers a promising approach for improving pancreatic cancer treatment by enhancing intratumoral drug retention and minimizing systemic side effects. The synergistic effects of SDT and chemotherapy demonstrate the potential of this strategy in achieving better therapeutic outcomes. |
| format | Article |
| id | doaj-art-a35c2bdba6b741d88e1489b01f35429c |
| institution | OA Journals |
| issn | 1424-8247 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-a35c2bdba6b741d88e1489b01f35429c2025-08-20T02:01:09ZengMDPI AGPharmaceuticals1424-82472024-12-011712166610.3390/ph17121666FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic CancerJian Wang0Nianhui Yu1Yunpeng Tang2Yingsheng Cheng3Hui Li4Department of Radiology, Sixth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, ChinaDepartment of Radiology, Sixth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, ChinaDepartment of Radiology, Sixth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, ChinaDepartment of Imaging Medicine and Nuclear Medicine, Tongji Hospital, Shanghai 200065, ChinaDepartment of Radiology, Sixth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China<b>Background:</b> Albumin-bound paclitaxel (nab-PTX) nanoparticles have been proven effective in treating advanced pancreatic cancer. However, the clinical application of nab-PTX nanoparticles is often associated with suboptimal outcomes and severe side effects due to its non-specific distribution and rapid clearance. This study aims to develop a novel nanoplatform that integrates sonodynamic therapy (SDT) and chemotherapy to enhance treatment efficacy and reduce systemic side effects. <b>Methods:</b> Bovine serum albumin (BSA) was conjugated with chlorin e6 and paclitaxel (PTX) to form stable nanoparticles (NPs). These NPs were then incorporated into a biodegradable poly(lactic-<i>co</i>-glycolic acid)–<i>b</i>-polyethylene glycol–<i>b</i>–poly(lactic-<i>co</i>-glycolic acid) hydrogel for targeted drug delivery. The system’s stability and drug release profile were analyzed, followed by in vitro studies to evaluate cellular uptake and cancer cell killing efficacy. In vivo evaluation was performed using pancreatic cancer xenograft models, with intratumoral injection of the drug-loaded hydrogel. <b>Results:</b> The developed hydrogel system demonstrated enhanced stability and sustained release of PTX. In vitro analyses revealed significant cellular uptake and synergistic cancer cell killing effects through combined SDT and chemotherapy. In vivo studies showed prolonged intratumoral retention of the drug and remarkable inhibition of tumor growth. <b>Conclusions:</b> This novel nanoplatform offers a promising approach for improving pancreatic cancer treatment by enhancing intratumoral drug retention and minimizing systemic side effects. The synergistic effects of SDT and chemotherapy demonstrate the potential of this strategy in achieving better therapeutic outcomes.https://www.mdpi.com/1424-8247/17/12/1666pancreatic cancerchemotherapysonodynamic therapythermosensitive hydrogel |
| spellingShingle | Jian Wang Nianhui Yu Yunpeng Tang Yingsheng Cheng Hui Li FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer Pharmaceuticals pancreatic cancer chemotherapy sonodynamic therapy thermosensitive hydrogel |
| title | FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer |
| title_full | FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer |
| title_fullStr | FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer |
| title_full_unstemmed | FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer |
| title_short | FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer |
| title_sort | fda approved hydrogel mediated in situ sonodynamic and chemotherapeutic therapy for pancreatic cancer |
| topic | pancreatic cancer chemotherapy sonodynamic therapy thermosensitive hydrogel |
| url | https://www.mdpi.com/1424-8247/17/12/1666 |
| work_keys_str_mv | AT jianwang fdaapprovedhydrogelmediatedinsitusonodynamicandchemotherapeutictherapyforpancreaticcancer AT nianhuiyu fdaapprovedhydrogelmediatedinsitusonodynamicandchemotherapeutictherapyforpancreaticcancer AT yunpengtang fdaapprovedhydrogelmediatedinsitusonodynamicandchemotherapeutictherapyforpancreaticcancer AT yingshengcheng fdaapprovedhydrogelmediatedinsitusonodynamicandchemotherapeutictherapyforpancreaticcancer AT huili fdaapprovedhydrogelmediatedinsitusonodynamicandchemotherapeutictherapyforpancreaticcancer |